Avalyn’s Phase 1a trial of AP02 assessed clinical tolerability and pharmacokinetic profiles in three SAD cohorts, up to a maximum 2.0 mg dose in HVs; two BAL cohorts in HVs; and one cohort of patients ...

The published long-term data suggests that the treatment could maintain its dominant position in the CF market.

Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines ...

A team from the Department of Cardiothoracic Surgery, Jawaharlal Nehru Medical College, Aligarh Muslim University, led by Prof. Mohd Azam Haseen, earned top honours at the IACTS Techno College CME ...

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that new data from a study in non-human primates (NHPs) has ...

Cambridge, MA, May 7, 2025 — Insilico Medicine ("Insilico"), a ... announced the company will present an oral presentation and three scientific posters at the American Thoracic Society (ATS ...

today announced that the Company will present a Late-Breaking scientific poster at the upcoming 2025 American Thoracic Society (ATS) International Conference taking place May 16-21, 2025 ...

Interested contributors now have until 19 May 2025 to submit abstracts for the IAEA's International Conference on Emergency Preparedness and Response.

The poster, titled “Outer Retina-Choroid en ... Ophthalmology of MERIT. About the Presentation: • Title: “Outer Retina-Choroid en face Image, ORC™: Characterization of A Novel Morphologic ...